Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ilodecakin. Schering-Plough Corp.

J K Marshall1

  • 1Division of Gastroenterology, Department of Medicine, Health Sciences Center, Room 4W8, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada. marshllj@fhs.csu.mcmaster.ca

Idrugs : the Investigational Drugs Journal
|August 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Declining Use of Corticosteroids for Crohn's Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial.

Journal of the Canadian Association of Gastroenterology·2021
Same author

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2013
Same author

Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2013
Same author

Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

Alimentary pharmacology & therapeutics·2013
Same author

Effect of wheat distillers dried grains with solubles or sugar beet pulp on prevalence of Salmonella enterica Typhimurium in weaned pigs.

Journal of animal science·2013
Same author

Clustering and stability of functional lower gastrointestinal symptom after enteric infection.

Neurogastroenterology and motility·2012
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Interleukin-10 (IL-10), also known as ilodecakin, is being studied for autoimmune diseases and cancers. Clinical trials are exploring its potential for Crohn's disease, rheumatoid arthritis, and HIV.

Area of Science:

  • Immunology
  • Pharmacology
  • Gastroenterology

Background:

  • Interleukin-10 (IL-10), developed by Schering-Plough as ilodecakin, is an immunomodulatory cytokine.
  • IL-10 has demonstrated potential in treating various inflammatory and autoimmune conditions.

Purpose of the Study:

  • To investigate the therapeutic potential of ilodecakin (IL-10) across a range of conditions.
  • To evaluate the efficacy and safety of IL-10 in ongoing clinical trials.

Main Methods:

  • Phase II and III clinical trials were conducted for Crohn's disease, ulcerative colitis, and rheumatoid arthritis.
  • Phase I trials were initiated for HIV-infected patients.
  • Ongoing studies are assessing IL-10 in acute lung injury, ischemia-reperfusion injury, multiple sclerosis, and psoriasis.

Related Experiment Videos

Main Results:

  • Ilodecakin has shown promise in treating inflammatory bowel disease.
  • Initial results in HIV patients indicated a transient decrease in viral load after a single IL-10 dose.
  • The drug is progressing through various clinical trial phases for multiple indications.

Conclusions:

  • Ilodecakin (IL-10) exhibits potential as a therapeutic agent for autoimmune diseases, inflammatory conditions, and certain viral infections.
  • Further clinical evaluation is warranted to establish the long-term efficacy and safety of IL-10.
  • Market predictions suggest significant commercial potential for ilodecakin.